摘要
目的观察巨刺法治疗偏头痛(肝阳上亢证)的临床疗效,及其对血浆一氧化氮(NO)、5-羟色胺(5-HT)的影响。方法将60例偏头痛患者随机分为治疗组和对照组各30例,治疗组采用巨刺法,对照组采用常规针刺治疗,分别观察两组患者治疗前、后的视觉模拟评分(VAS)、偏头痛生活特异性量表评分(MSQ)、疼痛症状积分的变化,并测量其治疗前后血浆NO、5-HT的含量。结果治疗组总有效率86.67%,明显高于对照组的63.33%(P<0.05),两组均能下降偏头痛患者的VAS评分、疼痛症状积分,改善MSQ评分(P<0.05),且治疗组优于对照组(P<0.05)。两组均能降低发作期NO含量(P<0.05),且治疗组优于对照组(P<0.05);治疗组能升高发作期、降低间歇期5-HT含量(P<0.05),而对照组对发作期及间歇期5-HT的改善均不明显(P>0.05)。结论巨刺法对肝阳上亢型偏头痛有明显的疗效,并能调节偏头痛患者血浆中NO、5-HT的含量,且优于常规针刺法。
Objective： To observe the curative effect of macro-needling therapy on liver yang exuberance syndrome migraine and its effect on NO and 5-HT. Methods： 60 patients with migraine were randomly divided into treatment group and control group with 30 cases in each group. The treatment group received macro-needling therapy while the control group received routine acupuncture treatment. The VAS, MSQ, change on pain evaluation were observed,the NO and 5-HT content in blood plasma was detected before and after the treatment. Results： The total effective rate was 86.67% in the treatment group which was significantly higher than 63.33% in the control group （P〈 0.05）. The VAS and pain evaluation were decreased and MSQ wasimproved in both groups. The result of treatment group was better than that of the control group （P〈 0.05）. The NO content at the stage of attack was lowered in both groups （P〈0.05） and the treatment group was better than the control group （P 〈 0.05）. The 5-HT content at the stage of attack was increased and it was decreased in the intermittment period in the treatment group （P〈 0.05）. While the improvement on 5-HT content at the stage of attack and in the intermittment period was not significant in the control group （P〉 0.05）. Conclusion： It has significant curative effect to treat liver yang exuberance syndrome migraine with macro-needling therapy. It can regulate NO and 5-HT content in blood plasma of the patients and is superior to routine acupuncture treatment.
出处
《中国中医急症》
2017年第1期118-121,共4页
Journal of Emergency in Traditional Chinese Medicine
基金
广东省中医药局科研资助项目(20141240)
深圳市科技研发资金条件与平台建设计划重点实验室项目(CXB201111250113A)
